Mikaela Naylon Give Kids a Chance Act of 2025

Enumerated powers · passes

Congress has authority under Article I, Section 8, Clause 3 (Commerce Clause) to regulate drugs and medical devices that move in interstate commerce. The FDA's oversight of clinical trials and priority review vouchers falls squarely within this power. Additionally, the bill's provisions to encourage pediatric cancer research are a valid exercise of the spending power and the general welfare clause (Article I, Section 8, Clause 1).

Bill of Rights · passes

The bill does not restrict speech, religion, assembly, press, petition, the right to bear arms, or any other enumerated right. It does not involve searches, seizures, self-incrimination, or criminal procedure. It imposes no punishment and does not affect trial rights. The bill is purely regulatory and incentive-based, with no impact on the Bill of Rights.

Individual liberty · passes

The bill does not restrict individual liberty. It authorizes clinical trials and provides incentives for drug development, which expands options for patients and families. It does not compel participation in trials or mandate any medical treatment. The burden on individuals is minimal and justified by the compelling interest in advancing pediatric cancer treatments.

Decentralization · passes

The bill addresses a national issue—pediatric cancer drug development—that cannot be effectively handled by individuals, local communities, or states alone due to the interstate nature of drug approval and the need for consistent federal standards. The FDA's role is necessary for national drug safety and efficacy. The bill does not consolidate decision-making upward beyond the minimum necessary; it delegates to federal agencies but does not preempt state authority over medical practice or licensing.

Due process and takings · passes

The bill does not deprive any person of life, liberty, or property without due process. It does not take private property for public use without just compensation. The priority review voucher program is a voluntary incentive, not a taking. The bill includes reporting and guidance requirements that ensure procedural regularity and transparency.